Personal Profile

Zhao Wei, Ph.D., is a professor and doctoral supervisor at Sun Yat-sen University. He is an overseas high-level talent (youth) and an introduced talent of Sun Yat-sen University. He serves as the vice chairman of the Guangdong Provincial Association for Brain Development and Brain Disease Prevention and Treatment and the executive director of the Guangdong Provincial Anatomical Society.

Zhao Wei obtained his bachelor's and doctoral degrees in biology at Nanjing University. He then conducted postdoctoral research at Baylor College of Medicine in the United States. After that, he worked as an assistant researcher at Methodist Hospital affiliated to Weill Medical College of Cornell University in the United States. In 2015, he joined the Zhongshan School of Medicine, Sun Yat-sen University as a professor and doctoral supervisor.

His current research focuses on the field of epigenetic regulation in the tumor microenvironment. Specifically, it includes:

  1. Revealing the subpopulations of cells in the tumor microenvironment through single-cell transcriptome and epigenome analysis and identifying key epigenetic factors.
  2. Exploring the functions of regulatory factors of RNA modification and histone modification in the fate determination of cells in the tumor microenvironment.
  3. Developing the application of epigenetic drugs in tumor treatment.

To date, he has published more than 30 papers in international authoritative academic journals such as Cell (2013, first author), Cancer Research (2019, corresponding author), Science Advances (2020, corresponding author), Signal Transduction and Targeted Therapy (2020, corresponding author), Advanced Science (2020, 2021, corresponding author), etc., among which he has 18 papers as a corresponding author (including co-corresponding author).

Graduate Student Training

We welcome graduate students who are passionate about scientific research and have a tenacious character to join our team. Professor Zhao Wei will provide full guidance and maximum support. Currently, many graduate students in his team have published high-level papers in internationally influential journals.

For more information about Professor Zhao Wei's team, please visit the laboratory website: http://www.zhaolaboratory.com/

Academic Achievements
Publication Status of Corresponding Author Papers in the Past Three Years (* indicates corresponding author)

  1. Pharmacological Inhibition of Core Regulatory Circuitry Liquid-liquid Phase Separation Suppresses Metastasis and Chemoresistance in Osteosarcoma. Lu B, Zou C, Yang M, He Y, He J, Zhang C, Chen S, Yu J, Liu K, Cao Q, and Zhao W* Advanced Science (Accept). 2021. 影响因子：16.806
  2. Interplay of m6A and histone modifications contributes to temozolomide resistance in glioblastoma. Li FX, Chen SY, Yu JM, Gao ZX, Sun ZY, Yi Y, Long T, Zhang CX, Li YZ, Pan YM, Qin CY, Long WY*, Liu Q*, Zhao W*. Clinical and Translational Medicine (Accept). 2021. 影响因子：11.429
  3. Nanomaterial-Facilitated Cyclin Dependent Kinase 7 Inhibition Suppresses Gallbladder Cancer Progression via Targeting Transcriptional Addiction. Huang CS, Xu QC, Dai CL, Wang LY, Tien YC, Li FX, Su Q, Huang XT, Wu J, Zhao W*, Yin XY. ACS Nano (Accept).2021. 影响因子：15.881
  4. HNRNPC impedes m6A-dependent anti-metastatic alternative splicing events in pancreatic ductal adenocarcinoma. Huang  XT, Li JH, Zhu XX, Huang CS, Gao ZX, QC, Zhao W*, Yin XY*. Cancer Letters (Accept). 2021. 影响因子：8.679
  5. Nanoparticle Enhanced Combination Therapy for Stem-like Progenitors Defined by Single-Cell Transcriptomics in Chemotherapy-Resistant Osteosarcoma. Wang L, Huang X, You X, Yi T, Lu B, Liu J, Lu G, Ma M, Zou C, Wu J*, and Zhao W*. Signal Transduction and Targeted Therapy, 2020 Sep 25;5(1):196. 影响因子：18.187
  6. Interplay of m6A and H3K27 trimethylation restrains inflammation during bacterial infection. Wu C, Chen W, He J, Jin S, Liu Y, Yi Y, Gao Z, Yang J, Yang J*, Cui J*, and Zhao W*. Science Advances. 2020 Aug 19:Vol. 6, no. 34, eaba0647. 影响因子：14.163
  7. Targeting Super-Enhancers via Nanoparticle-facilitated BRD4 and CDK7 Inhibitors Synergistically Suppresses Pancreatic Ductal Adenocarcinoma. Huang CS, You X, Dai C, Xu QC, Li F, Wang L, Huang XT, Wang JQ, Li SJ, Gao Z, Wu J*, Yin XY*, and Zhao W*. Advanced Science. 2020 Feb 16;7(7):1902926. 影响因子：16.806
  8. Epigenetic Profiling Identifies LIF as a Super-enhancer-Controlled Regulator of Stem Cell-like Properties in Osteosarcoma. Lu B, He Y, He J, Wang L, Liu Z, Yang J, Gao Z, Lu G, Zou C*, Zhao W*. Mol Cancer Res. 2020 Jan;18(1):57-67. 影响因子：5.852
  9. MFAP5 facilitates the aggressiveness of intrahepatic Cholangiocarcinoma by activating the Notch1 signaling pathway.Li JH, Zhu XX, Li FX, Huang CS, Huang XT, Wang JQ, Gao ZX, Li SJ, Xu QC, Zhao W*, Yin XY*. J Exp Clin Cancer Res. 2019 Nov 27;38(1):476. 影响因子：11.161
  10. Isoform-specific involvement of Brpf1 in expansion of adult hematopoietic stem and progenitor cells. He Q, Hong M, He J, Chen W, Zhao M, Zhao W*. J Mol Cell Biol. 2019 Sep 30. 影响因子：6.216
  11. N6-methyladenosine Modulates Nonsense-mediated mRNA Decay in Human Glioblastoma. Li F, Yi Y, Miao Y, Long W, Long T, Chen S, Cheng W, Zou C, Zheng Y, Wu X, Ding J, Zhu K, Chen D, Xu Q, Wang J, Liu Q, Zhi F, Ren J, Cao Q*, Zhao W*. Cancer Res. 2019 Sep 17. 影响因子：12.701

Research Projects

  1. General Project of the National Natural Science Foundation of China, 2020 - 2023, Project Leader.
  2. General Project of the National Natural Science Foundation of China, 2018 - 2021, Project Leader.
  3. Key Project of the National Key R & D Program on Stem Cells and Translational Research, 2017 - 2021, Task Leader.
  4. General Project of the National Natural Science Foundation of China, 2016 - 2019, Project Leader (Completed).